PLoS ONE (Jan 2013)

A patient with posterior cortical atrophy possesses a novel mutation in the presenilin 1 gene.

  • Emilia J Sitek,
  • Ewa Narożańska,
  • Beata Pepłońska,
  • Sławomir Filipek,
  • Anna Barczak,
  • Maria Styczyńska,
  • Krzysztof Mlynarczyk,
  • Bogna Brockhuis,
  • Erik Portelius,
  • Dorota Religa,
  • Maria Barcikowska,
  • Jarosław Sławek,
  • Cezary Żekanowski

DOI
https://doi.org/10.1371/journal.pone.0061074
Journal volume & issue
Vol. 8, no. 4
p. e61074

Abstract

Read online

Posterior cortical atrophy is a dementia syndrome with symptoms of cortical visual dysfunction, associated with amyloid plaques and neurofibrillary tangles predominantly affecting visual association cortex. Most patients diagnosed with posterior cortical atrophy will finally develop a typical Alzheimer's disease. However, there are a variety of neuropathological processes, which could lead towards a clinical presentation of posterior cortical atrophy. Mutations in the presenilin 1 gene, affecting the function of γ-secretase, are the most common genetic cause of familial, early-onset Alzheimer's disease. Here we present a patient with a clinical diagnosis of posterior cortical atrophy who harbors a novel Presenilin 1 mutation (I211M). In silico analysis predicts that the mutation could influence the interaction between presenilin 1 and presenilin1 enhancer-2 protein, a protein partner within the γ-secretase complex. These findings along with published literature support the inclusion of posterior cortical atrophy on the Alzheimer's disease spectrum.